Background and objective: Conventional methods to treat intraocular diseases are invasive or associated with adverse effects. A minimally invasive means of sustained-release drug delivery to the vitreous is required. This study evaluated a novel device for subtenon drug delivery to the vitreous, relative to a single subconjunctival injection. Methods: Sixty adult New Zealand White rabbits were randomly assigned to receive demethylvancomycin (DMV) by continuous subtenon delivery with the flow rate of 0.1 ml/hr for 24 hr, or as a single 0.3 ml subconjunctival injection in the right eyes. Rabbits were killed in subgroups of six at 1, 3, 6, 12 and 24 hr. The DMV concentration of the vitreous humour of the right eye was analysed by high-performance liquid chromatography. Results: Overall, the vitreous DMV concentration of the subtenon group was significantly higher than that of the subconjunctival group (F = 25.928, p = 0.001). The DMV concentration of the subtenon group was also significantly higher than that of the subconjunctival group at 3, 6, 12 and 24 hr (t = 2.457, 5.064, 3.085, 4.207; p = 0.04, 0.01, 0.018, 0.004, respectively). In the subtenon group, the DMV concentration reached maximum (2.41 AE 0.67 lg/ml) at 6 hr, and at 24 hr was 2.37 AE 1.23 lg/ml. In the subconjunctival group, the DMV concentration reached maximum (0.48 AE 0.27 lg/ml) at 1 hr and declined to 0.09 AE 0.05 lg/ml at 24 hr. Conclusion: Subtenon application with this novel minimally invasive design is an effective method for delivering an appropriate drug to the vitreous in a sustained and controllable amount.
Introduction
The current methods of ocular drug administration include topical application, intraocular injection, intravenous administration and periocular drug delivery. Each of these has advantages and disadvantages. Topical application cannot reach intraocular tissues at therapeutic concentrations due to corneal and bloodaqueous barriers (Ahmed 2003; Barar et al. 2008) , although recently reported pharmaceuticals may make topical applications possible for diseases of the posterior segment (Ohira et al. 2015; Shulman et al. 2015) . Intravenous administration can deliver drugs to intraocular tissues, but high doses are associated with systemic toxicities (Hughes et al. 2005; Janoria et al. 2007 ). Intraocular injection can bypass the blood-eye barrier and attain a high intraocular drug concentration, but repeated injections risk infectious endophthalmitis, retinal toxicity, haemorrhage, retinal detachment, glaucoma and cataract (Wu et al. 2008; Penha et al. 2011; Agard et al. 2015; Kanchanaranya et al. 2015; Michel et al. 2015) .
Periocular drug delivery, which depends on diffusion through the sclera, is less invasive than intraocular injection and holds great promise for drug delivery to the posterior segment (Ghate et al. 2007; Janoria et al. 2007 ), whether by transscleral or anterior pathways, or via systemic circulation through the choroid (Ghate & Edelhauser 2006) . The sclera covers~80% of the ocular surface and offers a relatively large area for drug administration; the uniform collagen composition of the sclera also makes it more permeable than the cornea. Early studies demonstrated that the permeability of sclera tissue is based on steady flux. To diffuse through the sclera and achieve a therapeutic concentration in ocular tissues, drugs must maintain contact with the sclera for an adequate time (Olsen et al. 1995) . Periocular routes of drug delivery, especially the transscleral route, are thus appropriate for sustained release. Factors that affect transscleral drug delivery include diffusion across the eyeball wall, active transport in the retinal pigment epithelium, and circulatory distribution and clearance (Ranta & Urtti 2006) . Periocular drug administration may be subconjunctival, retrobulbar, peribulbar or via the subtenon space. Current sustained-release transscleral drug delivery systems include gel formulations, polymeric implants, microspheres, liposomes and ocular inserts (Merodio et al. 2002; Ruel-Gariepy & Leroux 2004; Bourges et al. 2006; Ruiz-Moreno et al. 2006) . However, devices for sustained-release drug delivery require implantation into the vitreous cavity and cannot be precisely controlled (Baruch et al. 2005; Choonara et al. 2010; Eljarrat-Binstock et al. 2010) ; marketed examples include Vitrasert Ò , Retisert Ò and Iluvien TM . Herein we describe a controllable device for drug delivery in the subtenon space that avoids the necessity and limitations of intraocular implantation. Our device allows continuous infusion through the transscleral route to the vitreous, thus maintaining a steady-state flux of the drug and sufficient contact time between the drug and the sclera.
The primary focus of our research is the treatment of bacterial endophthalmitis. We administered demethylvancomycin (or N-demethylvancomycin; DMV), a member of the vancomycin group of glycopeptide antibiotics that are active against Gram-positive bacteria. These antibiotics share a similar heptapeptide trunk but vary in the number, type and placement of sugar substituents attached to the peptide nucleus (Hunt & Vernon 1981; Nagarajan 1993) . Their activity is dependent on the ability to bind to the cell wall (peptidoglycan) of Gram-positive bacteria, by forming the tripeptide L-lysine-D-alanine-Dalanine (Barna & Williams 1984) . Demethylvancomycin (DMV) differs from vancomycin only in that the methyl group on the amino group of the N-terminal residue of vancomycin has been replaced by hydrogen. This difference means that the effectiveness of 0.4 g DMV equals that of 0.5 g vancomycin (Yan et al. 2000) . Demethylvancomycin (DMV) was first isolated from a strain of the bacterium Amycolatopsis orientalis (formerly Streptomyces orientalis) from a soil sample and has been clinically used since 1967 (Lin et al. 1986 ).
The present study is a preliminary experiment to test this design, using rabbits. Its effectiveness is evaluated relative to that of a single subconjunctival injection. Specifically, we compared the DMV profiles of the vitreous humour of the two groups at time-points spanning 24 hr.
Materials and Methods

Animals
Adult New Zealand White rabbits, weighing between 2.0 and 2.5 kg and with animal health immunization certificates, were obtained from an authorized animal centre at Third Xiangya Hospital of Central South University. The rabbits were kept in individual cages under standardized conditions. The Animal Ethics Committee of Central South University and Changsha Aier Eye Hospital approved this study. The rabbits were treated in accordance with the guidelines and statements of the Association for Research in Vision and Ophthalmology.
Study design
Sixty rabbits were randomly assigned to receive drug delivery by either subtenon DMV infusion with the flow rate of 0.1 ml/hr for 24 hr or as a single 0.3 ml DMV subconjunctival injection. In each of the two groups, rabbits were also apportioned to one of five subgroups (n = 6, each) depending on the number of hours from the start of infusion (or injection) to death for collection of vitreous humour: 1, 3, 6, 12 or 24 hr.
To determine the DMV concentration in the vitreous cavity at the five time-points after drug administration, the rabbits of the appropriate subgroup were killed and the right eyes were enucleated. Left eyes were ignored, to avoid contralateral eye effects (Abdulrazik et al. 2006; Burke et al. 1995) . Vitreous humour was collected for highperformance liquid chromatography analysis . Any values ≥109 the standard were considered contaminated, and these outliers were deleted to avoid biased errors in data processing. The same numbers of new samples were added for remeasurement.
Anaesthesia
The rabbits were intramuscularly anaesthetized with a compound preparation of xylazine (0.2 ml/kg; Lumianning II, Zhong-Lian, China; Lumianning II, also known as Sumianxin II, is widely used for basal anaesthesia of rodents and livestock in veterinarian medicine in China). According to the situation, an additional dose of 0.04 ml/kg may be added during the procedure by intramuscular or intravenous administration, but no more than half the initial dose. Sufficient anaesthesia was determined based on decreased respiration and heart rate, muscle relaxation, disappearance of corneal reflex and lack of autonomic activity. For topical anaesthesia, 0.5% proparacaine hydrochloride (Alcaine; Alcon-Couvreur, Puurs, Belgium) was used.
Drug delivery device for sustainable subtenon drug delivery Our simplified device for subtenon drug delivery has four main components ( Fig. 1 ). An indwelling needle (Insyte-W; Becton Dickinson, Suzhou, China) is constructed with an airfoil tail; the body is a polyvinyl chloride tube with small holes on the head. A tube (Syringe Pump Infusion Line, FRESENIUS KABI, Miekinia) connects this indwelling needle to a 10-ml syringe filled with DMV, which is placed into an auto-infusion pump. The machine parameters of the pump were as follows: infusion speed 0.1-300 ml/hr; infusion accuracy AE3%; machine accuracy AE3%; and infusion amount 0.1-9999.9 ml (product model BYZ-810T; Biyang, Changsha, China).
Surgical procedures
Rabbits in both the subtenon and subconjunctival injection groups were given sufficient anaesthesia before the surgical procedures (described above), and the conjunctival sac of the right eye was sterilized and topical anaesthesia eyedrops were applied.
In the subtenon drug delivery group, an eyelid speculum was inserted to expose the bulbar conjunctiva. The superotemporal bulbar conjunctiva was cut open, 2 mm from the edge of cornea. After bluntly separating the fascia between the capsule of tenon and the sclera, a 3-4 cm length of polyvinyl chloride tube with some small holes in the head (the indwelling needle; see description above) was sutured onto the surface of the sclera. The conjunctival incision was sewn up, and the indwelling needle with the airfoil tail connected to the tube was taped onto the head of the rabbit. The other end of the tube was connected to the autoinfusion pump (Fig. 2 ). An initial drug load was infused as a bolus of 0.3 ml DMV (20 mg/ml) followed by continuous infusion at the flow rate of 0.1 ml/hr into the subtenon of the rabbits. All the rabbits in the subtenon drug delivery group were kept in individual cages and provided with food and water during the drug administration (Fig. 3) .
Rabbits in the subconjunctival injection group received a subconjunctival injection of 0.3 ml DMV (20 mg/ml) at the site of superotemporal bulbar conjunctiva which was 3 mm from the edge of cornea after sufficient anaesthesia.
Sample collection
The six rabbits of each time-point subgroup were killed, and the right eyes were enucleated immediately. The eyeballs were washed with 0.9% saline to avoid residual drug adhering to the surface of the eyeballs. From the centre of the vitreous cavity, 0.3 ml of vitreous humour was aspirated via the pars plana using a 5-ml syringe with a 20G needle, with care to prevent damage to the lens. Samples were stored at À20°C before analysis.
Analytical procedures
Each sample (0.3 ml) was thawed at room temperature and placed in a 2-ml Eppendorf tube. After the addition of 20 ll, 68.0 lg/ml of the internal standard vancomycin solution and 20 ll 24% perchloric acid, the tube was vortexed for 3 min and stored at 4°C for 10 min. The tube was centrifuged at 16 688 g for 10 min at 4°C, and the supernatant was transferred to another clear Eppendorf tube; 10 ll of 6 M NaOH was added. The tube was vortexed for 1 min and centrifuged at 15 000 rpm for 10 min at 4°C, and 20 ll of the supernatant was injected onto the analytical column for highperformance liquid chromatography.
To determine the DMV concentration in the vitreous humour samples, high-performance liquid chromatography (LC-20A; Shimadzu, Tokyo, Japan) was used at the following parameters. The analytical column was an InertSustain C18 (4.6 9 250 mm, 5.0 lm; GL Sciences, Tokyo, Japan), and the oven temperature was set at 40°C. The mobile phase consisted of 30 mM potassium dihydrogen 
Statistical analysis
The STATISTICAL PACKAGE FOR THE SOCIAL SCIENCES (SPSS) 18.0 software (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis of data.
One-way analysis of variance was used to compare the overall difference between the subtenon infusion group and the subconjunctival injection group. The independent-samples t-test was used to compare the differences between the two groups at each timepoint. The significance level a was 0.05.
Results
In the subtenon infusion group, the peak vitreous DMV concentration (2.41 AE 0.67 lg/ml) was recorded at 6 hr of continuous infusion and still remained at the level of 2.37 AE 1.23 lg/ml at 24 hr (Table 1 ; Fig. 4 ). In the subconjunctival injection group, the peak vitreous DMV concentration (0.48 AE 0.27 lg/ml) occurred at 1 hr after the DMV injection, but decreased to 0.09 AE 0.05 lg/ml at 24 hr. In the subtenon group, the DMV concentration showed a decrease at 12 hr but to rise up to similar levels found at 6 and 24 hr. In the subconjunctival group, the DMV concentration was little higher at 12 hr than at 6 hr, but at 24 hr had fallen to its lowest level of the timepoints measured. Overall, one-way analysis of variance indicated that the DMV concentration in the subtenon infusion group was significantly higher than that of the subconjunctival injection group (F = 25.928, p = 0.001; Table 1 ). By the independent t-test, the DMV concentration in the subtenon infusion group was significantly higher than that of the subconjunctival injection group at 3, 6, 12 and 24 hr.
The DMV concentrations of each of the two groups at the five time-points were fitted to a linear model (Fig. 5) . In the subtenon drug infusion group, the plot of the DMV concentrations increased from a low at 1 hr to a high at 24 hr of continuous infusion (R 2 = 0.245). However, in the subconjunctival injection group the plot of the DMV concentrations trended downward from 1 to 24 hr after injection (R 2 = 0.113). In the subtenon infusion group, the correlation analysis showed that the vitreous DMV concentration was significantly and positively associated with the duration of drug infusion (r = 0.437, p = 0.027). In the subconjunctival injection group, the vitreous DMV concentration was significantly and negatively associated with the time since drug injection (r = À0.527, p = 0.003). However, there was no significant correlation between vitreous DMV concentrations and infusion dosage in the subtenon drug delivery group (r = 0.319, p = 0.085).
Discussion
Subconjunctival injection bypasses cornea-conjunctiva barrier. The rapid drug elimination from the subconjunctival space becomes a primary factor of the vitreous drug concentrations. Lacking adequate drug-sclera contacting times for crossing the sclera to permit the attainment of steady-state flux, the drug concentration in vitreous cavity following subconjunctival administration is very low (Behrens-Baumann & Martell 1988; Kalsi et al. 1991) ; therefore, enhancing the sclera permeability requires steady-state flux of drug in subconjunctival space.
In this study, we compared the vitreous DMV profile obtained using our simplified device for continuous infusion of the subtenon with that of a Fig. 3 . The rabbits were kept in individual cages and provided with food and water during the drug administration. single subconjunctival injection. We found that in rabbits treated with subtenon infusion, by 3 hr the DMV concentration was higher than the reported MIC of both methicillinresistant and methicillin-susceptible Staphylococcus species (Marchese et al. 1995; King & Phillips 2001; Amatya et al. 2014; Zorgani et al. 2015; Kshetry et al. 2016) . However, in the rabbits given the subconjunctival injection, the MIC was never achieved. Rather, the DMV concentration of the subtenon infusion group was significantly higher than that of the subconjunctival injection group at all time-points from 3 to 24 hr. In the present experiment, DMV was directly infused into the subtenon of rabbits via a polyvinyl chloride tube connected to an auto-infusion pump. The rate and quantity of drug administration could be controlled. Consequently, the time of contact between the drug and sclera was long enough to maintain a therapeutic and steady drug concentration in the vitreous cavity. At the one-hour time-point, the vitreous DMV concentration of the subtenon infusion and subconjunctival injection groups was similar (t = À1.642, p = 0.145). In the rabbits given a single subconjunctival injection, the peak DMV concentration (0.48 AE 0.27 lg/ml) occurred at one hour (the first timepoint measured). This concentration was significantly less than that of the group subjected to subtenon infusion, in which the highest DMV concentration was found at the 6-hr timepoint (2.41 AE 0.67 lg/ml; F = 25.928, p = 0.001). These results show that more drug molecules could permeate the eyeball wall into the vitreous cavity with continuous subtenon infusion than with a single subconjunctival injection.
Cyclophosphamide was firstly used for drug administration in subtenon of rabbits in our study. However, the results were disappointing that its metabolic pathway in vivo is via rather the decomposition of enzymes in liver than the absorption of vessels in local tissues (Boddy & Yule 2000) . Because our future studies concern infective endophthalmitis, DMV was used. Studies also showed that there was a time lag in the drug permeability of sclera (Olsen et al. 1998) . If the time duration of drug contacting with the sclera was too short, the drug cannot permeate into the vitreous cavity effectively. In the present study, this may explain, at least in part, why the DMV concentration in the vitreous cavity of the subtenon infusion group did not reach maximum until 6 hr after the start of infusion.
Collagen accounts for 75% of the dry weight of the sclera. Fibre size and constituent of collagen differ increasingly from central cornea to the sclera: the fibres of cornea are orderly arrayed, while those of sclera are branched and interwoven arrayed. Passive diffusion is the primary mechanism of drug permeation of sclera (Borcherding et al. 1975) . In the present study, for each experimental group we determined a linear plot of the DMV concentration values for all time-points (1, 3, 6, 12 and 24 hr) . In the subtenon infusion group, the positive slope of the linear plot increased from one hour to 24 hr (R 2 = 0.245). This indicates that it might be a cumulative effect of drug permeability due to the physiological property of sclera (Borcherding et al. 1975) .
By virtue of its larger surface area and permeability, the sclera provides an ideal approach for delivering drugs to posterior segment tissues, compared with the cornea. The permeability of the sclera depends on the molecular weight of the solutes, and drug molecules of larger radius require more time to cross the sclera (Prausnitz & Noonan 1998; Urtti 2006) . In our study, we designed a simplified device for subtenon drug delivery that employs a polyvinyl chloride tube connected to an auto-infusion pump. With this design, continuous drug delivery is achieved to the subtenon space at a controllable dosage (rate and quantity). In the subtenon infusion group, the DMV concentration in the vitreous differed significantly over the range of timepoints (p = 0.027); however, no significant difference was found between drug concentrations and infusion dosage (p = 0.085). This shows that the drug concentration in the vitreous increased with time, but not above a certain level, perhaps due to the selfregulation function of the blood-eye barrier (Banerjee et al. 2008) .
In the present study, in the subtenon infusion group the mean vitreous DMV concentration was lower at 12 hr than at either 6 or 24 hr. This may be due to the small sample size and individual variation of rabbits, or a possible blockage in the delivery tube due to the suspension formulation, although we checked the patency of the tube regularly. In addition, it is possible that a tube could be disturbed by the animal's scratching or bitten, although each rabbit was placed in a plastic collar. In our further studies, we will prevent these possibilities by designing a portable device for subtenon drug delivery to rabbits and expand our sample size to minimize experimental errors.
Despite the blood-eye and other membrane barriers, in our study the mean DMV concentration in the vitreous of rabbits subjected to subtenon drug delivery was >2 lg/ml. This is an effective therapeutic concentration for most endophthalmitis pathogens (Marchese et al. 1995; King & Phillips 2001; Amatya et al. 2014; Zorgani et al. 2015; Kshetry et al. 2016 ). Other investigators have reported comparatively high drug concentration to the vitreous, but by methods that are more invasive than the periocular that we describe here. This includes the research of Choi & Lee (1988) , reporting delivery of vancomycin by transscleral iontophoresis, and that of Liu et al. (2009) with a vancomycin-loaded scleral plug to deliver the antibiotic into the vitreous cavity directly. Transscleral iontophoresis is based on the damage effect of electric current to increase permeability of the tissue, with the potential risk of intraocular tissue damage (Pikal 2001) . The risks associated with the scleral plug to penetrate the eyeball wall are similar to those of intraocular injection. However, with the method we describe, we achieved therapeutic DMV concentrations in the vitreous humour that were higher than the MIC of Staphylococcus spp., with minimal damage, by continuous drug infusion of the subtenon space. What is more, studies have confirmed that the compromised blood-eye barrier caused by endophthalmitis can increase the permeability of drugs (Ferencz et al. 1999; Nau et al. 2010) . Therefore, we assume that continuous subtenon drug delivery is likely to inhibit or kill the microbe in the vitreous. Continuous subtenon drug delivery may be able to replace or supplement the conventional methods, such as intraocular injection and intravenous administration, which are currently used for treating endophthalmitis.
In conclusion, these preliminary results are encouraging. Our simplified experimental device for non-invasive periocular drug infusion allowed a sustainable drug concentration in the vitreous. We intend to proceed with our studies by applying this device to treat bacterial endophthalmitis in rabbits. Periocular subtenon drug delivery may be a promising approach for treating posterior segment diseases and endophthalmitis.
